Neuphoria Therapeutics (NEUP) Cash from Operations (2023 - 2026)
Neuphoria Therapeutics (NEUP) posted quarterly Cash from Operations of 3400000.0 for Q1 2026, down 129.69% year-over-year from 11453452.0 in Q1 2025, and up 46.88% quarter-over-quarter from 6400000.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) Cash from Operations (2023 - 2026) Analysis & Trends
Neuphoria Therapeutics (NEUP) has reported Cash from Operations for 4 consecutive years, with 3400000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 129.69% year-over-year to 3400000.0; the TTM figure through Mar 2026 stood at 17162302.0 (down 2734.23% YoY), while the FY2025 annual figure was 100000.0, up 100.68% from the prior year.
- Cash from Operations grew to 3400000.0 in Q1 2026 per NEUP's latest filing, from 6400000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 11453452.0 in Q1 2025 and bottomed at 6400000.0 in Q4 2025.
- Historically, Cash from Operations has averaged 2561888.82 across 4 years, with a median of 3562302.0 in 2025.
- Annual changes were most pronounced in 2025 — Cash from Operations surged 447.59% — and 2026, when it tumbled 129.69%.
- Neuphoria Therapeutics' Cash from Operations stood at 3945126.0 in 2023, then gained by 14.88% to 3358087.0 in 2024, then sank by 90.58% to 6400000.0 in 2025, then surged by 46.88% to 3400000.0 in 2026.
- Business Quant data shows NEUP's Cash from Operations at 3400000.0 in Q1 2026, 6400000.0 in Q4 2025, and 3800000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - | 728.46 Mn |
| 10 | Neuphoria Therapeutics | 21.54 Mn | 2.10 Mn | - | -3.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.40 Mn |
| Mar 31, 2026 | -3.40 Mn |
| Dec 31, 2025 | -6.40 Mn |
| Dec 31, 2025 | -6.40 Mn |
| Sep 30, 2025 | -3.80 Mn |
| Sep 30, 2025 | -3.80 Mn |
| Jun 30, 2025 | -3.56 Mn |
| Jun 30, 2025 | -3.56 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Mar 31, 2025 | 11.45 Mn |
| Dec 31, 2024 | -3.36 Mn |
| Dec 31, 2024 | -3.36 Mn |
| Sep 30, 2024 | -4.43 Mn |
| Sep 30, 2024 | -4.43 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Jun 30, 2024 | -3.01 Mn |
| Mar 31, 2024 | -3.30 Mn |
| Mar 31, 2024 | -3.30 Mn |
| Dec 31, 2023 | -3.95 Mn |
| Dec 31, 2023 | -3.95 Mn |